INCYIncyte
$119.69+29% 1Y
$119.69
$90.3052 weeks$129.88
What has happened
INCY in its own filings
Nothing in INCY's filing record raises a hard flag: no restatement, late filing, bankruptcy or delisting notice, and no auditor change next to one. That is the common case, not a distinction.
513
Events found in the filings · across 2,620 filings · the record starts in 1996
- Hard flags
- none
Hard flags
- Most recent filing
- Oct 29, 2026
Most recent filing · Form 10-Q
- Record starts
- May 15, 1996
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filingsame week as a year ago
- expected around Feb 9, 2027
- SEC comment-letter activity34 occurrences
- 2020-04-13
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Earnings release
Incyte Reports Third Quarter 2026 Financial Results and Provides Business Updates.
The press release on sec.gov ↗ - Other event
Incyte Corporation (the “Company”) today announced that it has entered into an agreement with the U.S. Centers for Medicare & Medicaid Services (“CMS”) intended to improve access to medicines for American patients while supporting continued U.S. biopharmaceutical innovation.
Form 8-K on sec.gov ↗ - Earnings release
Incyte Reports Second Quarter 2026 Financial Results and Provides Business Updates.
The press release on sec.gov ↗
Earlier reports (8)›
- Other event
On July 6, 2026, Incyte Corporation (the “Company”) issued a press release announcing it has completed its previously announced acquisition of Vega Therapeutics, Inc., a wholly owned subsidiary of Star Therapeutics LLC (“Vega Therapeutics”)
Form 8-K on sec.gov ↗ - Other event
Incyte Corporation (the “Company”) today announced that it has reached an agreement with the Centers for Medicare & Medicaid Services (“CMS”) to resolve the Company’s litigation related to the application of Medicaid rebate rules to Opzelura ® (ruxolitinib) cream.
Form 8-K on sec.gov ↗ - Other event
On June 8, 2026, Incyte Corporation (the “Company”) issued a press release announcing it had entered into a definitive agreement to acquire Vega Therapeutics, Inc., a wholly owned subsidiary of Star Therapeutics, LLC (“Vega Therapeutics”)
Form 8-K on sec.gov ↗ - Earnings release
Incyte Reports First Quarter 2026 Financial Results and Provides Business Updates.
The press release on sec.gov ↗ - Director or officer change
On March 26, 2026, Susanne Schaffert notified Incyte Corporation (the “Company”) that she was resigning from the Company’s Board of Directors (the “Board”), effective as of April 15, 2026.
Form 8-K on sec.gov ↗ - Director or officer change
On March 25, 2026, Incyte Corporation (the “Company”) announced title changes for certain current members of its executive leadership team, effective immediately.
Form 8-K on sec.gov ↗ - Other event
On February 27, 2026, the U.S. Food and Drug Administration (“FDA”) issued a Complete Response Letter (“CRL”) for the supplemental Biologics License Application (“sBLA”) for Zynyz® (retifanlimab-dlwr) injection (375mg) for an additional indication for the treatment of adult patients with metastatic non-small cell lung …
Form 8-K on sec.gov ↗ - Earnings release
Incyte Reports Fourth Quarter and Full Year 2025 Financial Results.
The press release on sec.gov ↗
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…
Biotechnology
The closest names by size in the same industry